TABLE 4.

Univariate and multivariate analyses of genetic and nongenetic factors for tenofovir plasma concentrations

Factor	Univariate analysis			Multivariate analysisa
	B	95% CIb	P valuec	B	95% CI	P valuec
Female	13.986	−3.079 to 31.052	0.107
Age	0.183	−1.002 to 1.368	0.760
Body wt	−0.918	−1.622 to −0.214	0.011*	−0.861	−1.494 to −0.229	0.008**
eGFRd	−0.970	−1.420 to −0.520	<0.001*	−0.934	−1.375 to −0.492	<0.001**
Hepatitis B virus positive	−12.241	−29.541 to 5.059	0.164
Hepatitis C virus positive	−0.275	−31.721 to 31.171	0.986
Duration of tenofovir treatment	−0.385	−4.677 to 3.907	0.860
Concomitant RTV-boosted PIe	40.088	22.998 to 57.177	<0.001*	29.231	12.649 to 45.813	0.001**
ABCC2 −24 CT or TT	−3.435	−21.352 to 14.482	0.706
ABCC2 1249 GA or AA	0.217	−21.989 to 22.422	0.984
ABCC2 3972 CT or TT	−6.675	−24.279 to 10.930	0.455
ABCC4 3463 AG or GG	−12.127	−29.791 to 5.536	0.177
ABCC4 4131 TG or GG	18.464	−1.690 to 38.619	0.072*	25.180	7.049 to 43.310	0.007**

^aFactors with P values of <0.1 in the univariate analysis were entered into the multivariate analysis.

^bCI, confidence interval.

^c*, P < 0.1; **, P < 0.05.

^dCalculated by use of the MDRD formula.

^eRTV, ritonavir; PI, protease inhibitor.